

Japan launches new treatment for chronic constipation

25 May 2022 | News

A new dosage form added to polyethylene glycol chronic constipation treatment for the first time in Japan

EA Pharma and its parent company Eisai, and Mochida Pharmaceutical have announced today that “MOVICOL HD”, a chronic constipation treatment, has been launched by EA Pharma and Mochida.

MOVICOL HD is a high dose formulation of existing “MOVICOL LD”, the first polyethylene glycol indicated for treatment of chronic constipation in Japan. MOVICOL HD contains the same active ingredients in double the quantity of MOVICOL LD per sachet.

For the patients who have previously used 2 sachets of MOVICOL LD per dose, MOVICOL HD can save the time and effort of opening multiple sachets, increasing convenience, reducing the economic burden and reducing packing waste.

MOVICOL LD and MOVICOL HD (collectively MOVICOL) are indicated for children of 2 years and above and adults patients. MOVICOL is a powdered medicine to be dissolved in water before administration, which enables suitable increase or decrease of the dose to obtain the preferred stool consistency.

Outside Japan, MOVICOL has been marketed in mainly in Europe by Norgine B.V. under the brand name *MOVICOL* and is used by many patients with chronic constipation. In Japan, the Evaluation Committee on Unapproved or Off-Labeled Drugs with High Medical Needs of Ministry of Health, Labour and Welfare recognized the “high unmet medical needs” of polyethylene glycol preparations for chronic constipation, and Ajinomoto Pharmaceuticals(now EA Pharma) developed MOVICOL with Mochida for oral chronic constipation treatment in pediatric and adult patients in Japan under the license granted by Norgine to Ajinomoto Pharmaceuticals Co., Ltd. (now EA Pharma).